Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 6/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | GPR39 | O43194 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468233 | 0.86 | HSD11B1 (0.51) | PANK3GPR119HSD11B1CHRM1SMO | |
| SCHEMBL5481967 | 0.84 | HSD11B1 (0.51) | PANK3GPR119HSD11B1CHRM1SMO | |
| SCHEMBL14581838 | 0.82 | HSD11B1 (0.48) | PANK3GPR119CNR2HSD11B1CHRM1 | |
| SCHEMBL5466689 | 0.81 | HSD11B1 (0.48) | PANK3GPR119HSD11B1CHRM1SMO | |
| SCHEMBL5468420 | 0.79 | HSD11B1 (0.48) | PANK3GPR119HSD11B1CHRM1SMO | |
| SCHEMBL5483019 | 0.78 | HSD11B1 (0.51) | PANK3GPR119HSD11B1CHRM1SMO | |
| SCHEMBL14581841 | 0.78 | HSD11B1 (0.45) | PANK3GPR119CNR2HSD11B1SMO | |
| SCHEMBL14581819 | 0.74 | KDM4E (0.52) | PANK3GPR119HSD11B1CHRM1SMO | |
| SCHEMBL4373883 | 0.72 | HSD11B1 (0.70) | HSD11B1 | |
| SCHEMBL12640412 | 0.72 | HSD11B1 (0.49) | PANK3GPR119CNR2HSD11B1SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | AGOURON PHARMACEUTICALS, INC | 2007-02-01 | — | — | US | disclosed |
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | AGOURON PHARMACEUTICALS, INC | 2007-02-01 | — | — | US | disclosed |
| WO-2006106423-A2 | AMINO SULFONYL DERIVATIVES AS INHIBITORS OF HUMAN 11-.BETA.-HYDROSYSTEROID DEHYDROGENASE | PFIZER INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | HSD11B1, HSD11B2, HSD17B11 | PANK3 2984/4885GPR119 29/4885CNR2 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.